Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007196
Chunk: 17

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 17
---
 this prospectus forms a part, for the provisions that are important to you.

General

We are a public limited company
organized under the laws of England and Wales under registered number 09216368. Our registered office is 1 Caspian Point, Caspian Way,
Cardiff, CF10 4DQ, United Kingdom. The principal legislation under which we operate and our shares are issued is the United Kingdom Companies
Act of 2006, or the Companies Act.

Issued Share Capital

Our issued share capital as of December 31, 2024 and April 1, 2025 was 6,685,918,822
Ordinary Shares and 25,617,408,922 Ordinary Shares, respectively, with each Ordinary Share having a nominal value of £0.00005 per
share. Each issued Ordinary Share is fully paid. We currently have 1,000,001 A Deferred Shares, 4,063,321,420 B Deferred Shares, 126,547,389,518
C Deferred Shares, and no preference shares in our issued share capital.

There is no limit to the number
of Ordinary Shares or preference shares that we are authorized to issue, as the concept of authorized capital is no longer applicable
under the provisions of the Companies Act. There are no conversion rights, redemption provisions or sinking fund provisions relating to
any Ordinary Shares.

We are not permitted under
English law to hold our own Ordinary Shares unless they are repurchased by us and held in treasury. We do not currently hold any of our
own Ordinary Shares.

History of Share Capital

Since January 1, 2022, our
issued share capital has changed as provided below.

On March 22, 2022, we issued
one Ordinary Share upon the exercise of one warrant issued in February 2019 to a certain institutional investor at an exercise price of
£200 per share.

On
May 3, 2022, we issued 1,250 Ordinary Shares to be purchased under the Biodexa Pharmaceuticals Share Incentive Plan, or the Share Incentive
Plan, at £0.02 per share to the trust of the Share Incentive Plan.

On
August 3, 2022, we issued warrants to purchase 16,666 Ordinary Shares to a certain institutional investor at an exercise price of £2.70
per share.

On
September 26, 2022, we effected a ratio change to the Depositary Shares